Search Result
Results for "
obstructive pulmonary disease
" in MedChemExpress (MCE) Product Catalog:
7
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-D0205A
-
-
-
- HY-15545
-
-
-
- HY-156963
-
|
FP-025
|
MMP
|
Inflammation/Immunology
|
|
Aderamastat (FP-025) is an orally active matrix metalloproteinase 12 (MMP-12) inhibitor. Aderamastat can be used for the research of asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis .
|
-
-
- HY-121491
-
-
-
- HY-14786
-
|
GSK233705
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Darotropium bromide (GSK233705), a long-acting muscarinic antagonist and an inhaled anticholinergic, can be used for the research of chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-120322
-
|
|
mAChR
|
Others
|
|
MK-0969 is a M3 antagonist. MK-0969 can be used for research about chronic obstructive pulmonary disease and urinary incontinence .
|
-
-
- HY-111144
-
|
AZD0548; LAS100977
|
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Abediterol (LAS100977) is an inhaled long-acting β2-adrenoceptor agonist (LABA) and can be used for the research of asthma and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-D0205AR
-
|
|
Enterovirus
|
Infection
Inflammation/Immunology
|
|
Carbocisteine (Standard) is the analytical standard of Carbocisteine. This product is intended for research and analytical applications. Carbocisteine, a mucolytic agent, can be used for the research of chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-15502
-
-
-
- HY-105762A
-
|
|
Others
|
Cardiovascular Disease
|
|
Etamiphyllin camsylate is a cardiac stimulant with oral activity that increases cardiac output without increasing heart rate. Etamiphyllin camsylate is also a respiratory stimulant used for respiratory failure, as Etamiphyllin camsylate relaxes the smooth muscles of the bronchi and bronchioles, thereby opening up the airways to relieve chronic obstructive pulmonary disease .
|
-
-
- HY-109094
-
|
EC-18
|
Others
|
Inflammation/Immunology
|
|
Mosedipimod is a monoacetyldiaglyceride that can be isolated from Cervus nippon Temminck. Mosedipimod is an orally active Toll-Like Receptor signaling inhibitor. Mosedipimod attenuates airway infammation by reducing myeloperoxidase expression in lung tissue. Mosedipimod is used in chronic obstructive pulmonary disease research .
|
-
-
- HY-137976
-
|
Penequinine hydrochloride
|
mAChR
NF-κB
|
Inflammation/Immunology
|
|
Penehyclidine (Penequinine) hydrochloride, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine hydrochloride activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine hydrochloride can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .
|
-
-
- HY-142119
-
|
|
mAChR
NF-κB
|
Inflammation/Immunology
|
|
Penehyclidine, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .
|
-
-
- HY-70069
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease .
|
-
-
- HY-10469
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
GSK256066 is a selective and high-affinity phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 is developed for the research of chronic obstructive pulmonary disease .
|
-
-
- HY-112726
-
|
BI-1467335
|
Monoamine Oxidase
|
Inflammation/Immunology
|
|
PXS-4728A (BI-1467335) is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO). PXS-4728A ameliorates chronic obstructive pulmonary disease in mice .
|
-
-
- HY-B0241
-
|
Sch 1000
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .
|
-
-
- HY-B1332
-
|
Sch 1000 bromide hydrate
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Ipratropium bromide (Sch 1000) hydrate is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .
|
-
-
- HY-154795
-
|
|
Caspase
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Magnesium isoglycyrrhizinate hydrate is the active component found in licorice plant (Glycyrrhiza glabra). Magnesium isoglycyrrhizinate hydrate exhibits anti-inflammatory activity through NLRP3 inflammasome pathway, and attenuates the chronic obstructive pulmonary disease in rats .
|
-
-
- HY-155692
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
PDE4-IN-13 is a PDE4 inhibitor with an IC50 of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties， and can be used for chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
|
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-B0944
-
|
|
Bacterial
|
Inflammation/Immunology
|
|
Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .
|
-
-
- HY-148092
-
|
|
STAT
|
Inflammation/Immunology
Cancer
|
|
PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research [1].
|
-
-
- HY-19393
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
SCH 351591 is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 58 nM. SCH 351591 can inhibit all 4 PDE4 subtypes (A, B, C, and D). SCH 351591 has the potential for the asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-B0241R
-
|
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Ipratropium (bromide) (Standard) is the analytical standard of Ipratropium (bromide). This product is intended for research and analytical applications. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .
|
-
-
- HY-B1332R
-
|
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Ipratropium (bromide hydrate) (Standard) is the analytical standard of Ipratropium (bromide hydrate). This product is intended for research and analytical applications. Ipratropium bromide (Sch 1000) hydrate is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .
|
-
-
- HY-B0944R
-
|
|
Bacterial
|
Inflammation/Immunology
|
|
Pidotimod (Standard) is the analytical standard of Pidotimod. This product is intended for research and analytical applications. Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .
|
-
-
- HY-106448
-
|
MR 889
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
Midesteine (MR 889) is a proteinase inhibitor that can inhibit porcine pancreatic elastase, human neutrophil elastase and bovine chymotrypsin. Midesteine has the potential for chronic obstructive pulmonary disease (COPD) and chronic bronchitis research .
|
-
-
- HY-146346
-
|
|
PROTACs
HDAC
|
Inflammation/Immunology
|
|
HD-TAC7 is a potent PROTAC HDAC degrader with IC50 values of 3.6 μM, 4.2 μM and 1.1 μM for HDAC1, HDAC2 and HDAC3, respectively. HD-TAC7 can decreases NF-κB p65 in RAW 264.7 macrophages. HD-TAC7 can be used for the research of inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-148096
-
|
|
STAT
|
Inflammation/Immunology
Cancer
|
|
STAT6-IN-1 (compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer .
|
-
-
- HY-151198
-
|
|
mAChR
Adrenergic Receptor
Calcium Channel
|
Inflammation/Immunology
Endocrinology
|
|
CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-131910
-
|
|
PI3K
Cytochrome P450
|
Inflammation/Immunology
|
|
IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56∼83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-132831
-
|
Somalix; RO-7486967; IZD334
|
NOD-like Receptor (NLR)
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease
|
-
-
- HY-143721
-
|
|
Monoamine Oxidase
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
|
-
-
- HY-143723
-
|
|
Monoamine Oxidase
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
|
-
-
- HY-10790
-
|
SB-207499
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC50s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC50=74, 65, >100, and 83 μM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-107909
-
|
1,3-Dimethylxanthine sodium glycinate; Theo-24 sodium glycinate
|
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-119799
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
UK-500001 is an orally active inhibitor for phosphodiesterase 4 (PDE4), which inhibits PDE4D3 (IC50 is 0.28 nM), PDE4B2 (IC50 is 22.8 nM), PDE4A4 (IC50 is 26.1 nM) and PDE4C2 (IC50 is 271 nM). UK-500001 exhibits anti-inflammatory efficacy and inhibits TNF-α and IFN-γ release in human and rodent macrophagic cell lines in nanomolar levels. UK-500001 ameliorates chronic obstructive pulmonary disease (COPD) and asthma .
|
-
-
- HY-120802
-
|
AZD-8871; LAS191351
|
mAChR
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .
|
-
-
- HY-120802A
-
|
AZD-8871 saccharinate; LAS191351 saccharinate
|
mAChR
Adrenergic Receptor
|
Infection
Inflammation/Immunology
|
|
Navafenterol (AZD-8871) saccharinate is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol saccharinate can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .
|
-
-
- HY-B0809
-
|
1,3-Dimethylxanthine; Theo-24
|
Phosphodiesterase (PDE)
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
Endogenous Metabolite
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-B0809B
-
|
1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate
|
Endogenous Metabolite
Phosphodiesterase (PDE)
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-B0809A
-
|
1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate
|
Phosphodiesterase (PDE)
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
Endogenous Metabolite
|
Cancer
|
|
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-147518
-
|
|
p38 MAPK
|
Inflammation/Immunology
|
|
p38-α MAPK-IN-5 (compound 4e) is a potent p38α inhibitor with IC50s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-U00105
-
|
|
mAChR
|
Inflammation/Immunology
|
|
Oxitropium bromide is an mAChR antagonist used as an anticholinergic bronchodilator agent for the treatment of asthma and chronic obstructive pulmonary disease.
|
-
-
- HY-105092
-
-
-
- HY-B0809S1
-
|
1,3-Dimethylxanthine-d3; Theo-24-d3
|
Endogenous Metabolite
Adenosine Receptor
HDAC
TNF Receptor
Interleukin Related
Phosphodiesterase (PDE)
Apoptosis
Isotope-Labeled Compounds
|
Cancer
|
|
Theophylline-d3 is deuterated labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-10404
-
-
-
- HY-153192
-
|
BI 1015550
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-B1096
-
|
Ethamivan; N,N-Diethylvanillamide
|
Others
|
Neurological Disease
|
|
Etamivan (Ethamivan), an orally active respiratory stimulant, is mainly used in the research of barbiturate overdose and chronic obstructive pulmonary disease .
|
-
- HY-153192A
-
|
BI 1015550 dihydrate
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Nerandomilast (BI 1015550) dihydrate is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast (dihydrate) has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-19830
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
AN3199 is a PDE4 inhibitor with an IC50 of 94.5 nM. AN3199 can be used for the research of inflammation-associated diseases such as asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-162878
-
|
|
PI3K
|
Inflammation/Immunology
|
|
CHF-6523 is an orally active PI3Kδ inhibitor that can be used in research related to chronic obstructive pulmonary disease (COPD) .
|
-
- HY-113692
-
|
|
Others
|
Others
|
|
AZD-9164 (bromide) is a long-acting muscarinic M3 antagonist. AZD-9164 (bromide) is promising for research of airways diseases, such as chronic obstructive pulmonary disease (COPD) or asthma .
|
-
- HY-161877
-
|
|
RSV
|
Infection
|
|
GS-7682 is an antiviral compound. GS-7682 has inhibitory activity against pneumoviruses and picornaviruses. GS-7682 can be used in the study of respiratory diseases such as asthma and chronic obstructive pulmonary disease .
|
-
- HY-14298
-
|
GSK-159797C
|
Adrenergic Receptor
|
Endocrinology
|
|
Milveterol hydrochloride is a long-acting β2-adrenergic receptor agonist. Milveterol hydrochloride can be used in study asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-108644
-
-
- HY-14144
-
|
LAS 34273; LAS-W 330
|
mAChR
|
Inflammation/Immunology
|
|
Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-14117
-
-
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
-
- HY-B1037S
-
|
Albuterol-d3; AH-3365-d3
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Salbutamol-d3 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
- HY-B1037S2
-
-
- HY-106564A
-
|
Ba 598Br; Flubron
|
Others
|
Inflammation/Immunology
|
|
Flutropium bromide (Ba 598Br) is a organic bromide salt of flutropium. Flutropium bromide shows an anticholinergic effect. Flutropium bromide effectively suppresses spasms and it can be used for the research of asthma and chronic obstructive pulmonary disease .
|
-
- HY-B1037S3
-
|
Albuterol-d9 acetate; AH-3365-d9 acetate
|
Adrenergic Receptor
|
Endocrinology
|
|
Salbutamol-d9 (acetate) is the deuterium labeled Salbutamol[1]. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
- HY-19929
-
|
CHF-6001
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Tanimilast (CHF-6001) is a novel highly potent and selective phosphodiesterase 4 inhibitor(IC50=0.026 ± 0.006 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration.Tanimilast is used for the research of obstructive lung diseases .
|
-
- HY-132831B
-
|
Somalix potassium; RO-7486967 potassium; IZD334 potassium
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Selnoflast (RO-7486967) Potassium, formerly Somalix/RG6418/IZD334, Selnoflast is an orally available inhibitor of NLRP3. Selnoflast is used in the study of systemic inflammation, such as ulcerative colitis and chronic obstructive pulmonary disease .
|
-
- HY-148093
-
|
|
STAT
|
Inflammation/Immunology
Cancer
|
|
PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [1].
|
-
- HY-132831A
-
|
Somalix calcium; RO-7486967 calcium; IZD334 calcium
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Selnoflast (RO-7486967) calcium Formerly known as Somalix/RG6418/IZD334, Selnoflast is an orally available inhibitor of NLRP3. Selnoflast is used in the study of systemic inflammation, such as ulcerative colitis and chronic obstructive pulmonary disease[1]/s.br/ .
|
-
- HY-109177
-
|
QBW251
|
CFTR
|
Inflammation/Immunology
|
|
Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research .
|
-
- HY-14189
-
|
R-411
|
Integrin
|
Inflammation/Immunology
|
|
Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
|
-
- HY-130786
-
|
BRL 30892
|
Phosphodiesterase (PDE)
|
Others
Inflammation/Immunology
|
|
Denbufylline (BRL 30892) is an inhibitor of phosphodiesterase-4 (PDE4). Denbufylline is able to block the degradation of intracellular cAMP (cyclic adenosine phosphate) thereby increasing the level of intracellular cAMP, which helps regulate a variety of cellular functions. Denbufylline can be used in the study of chronic obstructive pulmonary disease (COPD), asthma and other inflammatory diseases .
|
-
- HY-155611
-
|
|
Cathepsin
|
Inflammation/Immunology
|
|
Cathepsin C-IN-6 (compound 2) is a E-64c-hydrazideas based inhibitor of cathepsin C with anti-inflammatory activity. Cathepsin C-IN-6 inhibts activation of neutrophil elastase，exhibits potential efficacy in inflammatory diseases with high neutrophil load (e.g.，chronic obstructive pulmonary disease) .
|
-
- HY-19672
-
|
BAY 19-8004
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties .
|
-
- HY-14301
-
|
BI1744
|
Adrenergic Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Olodaterol (BI1744) is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .
|
-
- HY-14301A
-
|
BI1744 hydrochloride
|
Adrenergic Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Olodaterol (BI1744) hydrochloride is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .
|
-
- HY-107591B
-
|
|
IKK
|
Inflammation/Immunology
|
|
PF-184 is a potent and selective IKK-2 inhibitor (IC50: 37 nM) over rhIKK-1, IKKi, and more than 30 tyrosine and serine/threonine kinases. PF-184 can be used in the research of inflammation, such as asthma and chronic obstructive pulmonary disease .
|
-
- HY-19644
-
|
GSK 2256294
|
Epoxide Hydrolase
|
Cardiovascular Disease
|
|
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease .
|
-
- HY-P2797
-
|
AMCase, Serratia marcescens
|
Bacterial
|
Metabolic Disease
Inflammation/Immunology
|
|
Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer) .
|
-
- HY-14190
-
|
R-411 free base
|
Integrin
|
Inflammation/Immunology
|
|
Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
|
-
- HY-14144R
-
|
|
mAChR
|
Inflammation/Immunology
|
|
Aclidinium (Bromide) (Standard) is the analytical standard of Aclidinium (Bromide). This product is intended for research and analytical applications. Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-123862
-
|
|
PI3K
|
Inflammation/Immunology
|
|
LAS195319 is a potent inhibitor against PI3Kδ with an IC50 value of 0.5 nM. LAS195319 is also a highly selective inhibitor against an extensive panel of proteins, lipid kinases and GPCRs. LAS195319 causes an inhibition of neutrophil and eosinophil infiltration. LAS195319 is promising for research of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-B1810
-
|
C-78 free base
|
Adrenergic Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Tulobuterol (C-78 free base) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol is also a sympathomimetic agent used as a transdermal patch, and increases normal diaphragm muscle strength .
|
-
- HY-119708
-
|
RPL-554
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 with IC50s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-107046
-
|
|
Adenosine Receptor
|
Inflammation/Immunology
|
|
UK-432097 is a highly potent and selective A2AAR agonist with a pKi of 8.4 for human A2AAR. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research .
|
-
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
-
- HY-118848
-
|
|
Lipoxygenase
Leukotriene Receptor
|
Inflammation/Immunology
|
|
A63162 is a specific 5-lipoxygenase (5-LOX) inhibitor. A63162 inhibits mitogen (PHA)-induced horse mononuclear cell (BMC) proliferation and inhibits Calcimycin (HY-N6687)-induced leukotriene LTB4 synthesis at the same concentration. A63162 can be used in the study of chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease .
|
-
- HY-14301AR
-
|
|
Adrenergic Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Olodaterol (hydrochloride) (Standard) is the analytical standard of Olodaterol (hydrochloride). This product is intended for research and analytical applications. Olodaterol (BI1744) hydrochloride is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .
|
-
- HY-B1037
-
|
Albuterol; AH-3365
|
Adrenergic Receptor
ERK
|
Inflammation/Immunology
Cancer
|
|
Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-B0004
-
|
|
Adenosine Receptor
Phosphodiesterase (PDE)
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
|
-
- HY-W011733
-
|
C-78
|
Adrenergic Receptor
Influenza Virus
Antibiotic
|
Infection
Inflammation/Immunology
Endocrinology
|
|
Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength . Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation .
|
-
- HY-159686
-
|
|
Adrenergic Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Aclidinium is a long-acting muscarinic antagonist and long-acting β2-adrenoceptor (β2-AR) agonist with bronchodilator activity. Aclidinium can reduce hyperinflation of the lungs and increase lung function and exercise endurance time. Aclidinium is used in research on chronic obstructive pulmonary disease (COPD) .
|
-
- HY-P3293
-
|
POL6014
|
Elastase
|
Inflammation/Immunology
|
|
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF) .
|
-
- HY-P3293A
-
|
POL6014 TFA
|
Elastase
|
Inflammation/Immunology
|
|
Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF) .
|
-
- HY-B0241S
-
|
Sch 1000-d3
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Ipratropium-d3 (bromide) is the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC50 values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3].
|
-
- HY-B1810S
-
|
C-78-d9
|
Adrenergic Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Tulobuterol-d9 (hydrochloride) is the deuterium labeled Tulobuterol. Tulobuterol (C-78 free base) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol is also a sympathomimetic agent used as a transdermal patch, and increases normal diaphragm muscle strength[1].
|
-
- HY-124270
-
|
AR-C68397AA
|
Dopamine Receptor
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Sibenadet hydrochloride (AR-C68397AA) is a dual D2 dopamine receptor, beta2-adrenoceptor agonist with bronchodilator activity. Investigation in animal models of key chronic obstructive pulmonary disease (COPD) symptoms has demonstrated that Sibenadet hydrochloride effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea.
|
-
- HY-10437
-
|
MK-0633
|
Lipoxygenase
|
Inflammation/Immunology
|
|
Setileuton (MK-0633) is an inhibitor for 5-lipoxygenase, that inhibits the oxidation of arachidonic acid by recombinant human 5-LO, and the production of LTB4 in calcium ionophore-stimulated human whole blood, with IC50 of 3.9 and 52 nM, respectively .
|
-
- HY-14299
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
|
-
- HY-136239
-
|
Beclomethasone-17-monopropionate; 17-BMP
|
Glucocorticoid Receptor
Drug Metabolite
|
Inflammation/Immunology
|
|
Beclomethasone 17-propionate (Beclomethasone-17-monopropionate), an active metabolite of Beclomethasone dipropionate (HY-13571), is a glucocorticoid receptor (GR) agonist. Beclomethasone 17-propionate exhibits greater affinity for GR than Beclomethasone dipropionate. Beclomethasone 17-propionate effectively suppresses cytokine production in chronic obstructive pulmonary disease (COPD) lung macrophages .
|
-
- HY-B0241S1
-
|
Sch 1000-d7 (bromide)
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
|
Ipratropium-d7 (bromide)eis the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC50 values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3].
|
-
- HY-120595
-
|
RV568
|
p38 MAPK
Src
|
Inflammation/Immunology
|
|
JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma .
|
-
- HY-125050
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
KCA-1490 is a dual PDE3/4 inhibitor with IC50 values of 369 nM and 42 nM, respectively. KCA-1490 exhibits potent bronchodilatory and anti-inflammatory activity. KCA-1490 suppresses Histamine (HY-B1204)-induced bronchoconstriction in vivo, which is promising for research of asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-14299A
-
|
QAB149
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
|
-
- HY-149235
-
|
|
PI3K
|
Inflammation/Immunology
|
|
PI3Kδ-IN-12 (compound 13) is a PI3Kδ inhibitor (pIC50 = 5.8), with pKi values of 8.0/6.5/6.4/6.7 for PI3Kδ/γ/β/α, respectively. PI3Kδ-IN-12 can be used in the study of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-108047
-
|
|
Phosphodiesterase (PDE)
|
Metabolic Disease
Inflammation/Immunology
|
|
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .
|
-
- HY-155300
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC50 of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a Ki value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .
|
-
- HY-17465R
-
|
|
mAChR
|
Neurological Disease
Cancer
|
|
Glycopyrrolate (Standard) is the analytical standard of Glycopyrrolate. This product is intended for research and analytical applications. Glycopyrrolate (Glycopyrronium bromide), a quaternary ammonium derivative, is a muscarinic receptor antagonist. Glycopyrrolate has bronchoprotective effect and produces a beneficial effect on blood pressure. Glycopyrrolate can be used for the research of bronchial diseases .
|
-
- HY-17465
-
|
Glycopyrronium bromide; Glycopyrrolate bromide
|
mAChR
|
Neurological Disease
Cancer
|
|
Glycopyrrolate (Glycopyrronium bromide), a quaternary ammonium derivative, is a muscarinic receptor antagonist. Glycopyrrolate has bronchoprotective effect and produces a beneficial effect on blood pressure. Glycopyrrolate can be used for the research of bronchial diseases .
|
-
- HY-P9923
-
|
MEDI-563; BIW-8405
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
-
- HY-B0004R
-
|
|
Adenosine Receptor
Phosphodiesterase (PDE)
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
|
-
- HY-B1037R
-
|
Albuterol (Standard); AH-3365 (Standard)
|
Adrenergic Receptor
ERK
|
Inflammation/Immunology
Cancer
|
|
Salbutamol (Standard) is the analytical standard of Salbutamol. This product is intended for research and analytical applications. Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-W011733R
-
|
|
Adrenergic Receptor
Influenza Virus
Antibiotic
|
Infection
Inflammation/Immunology
Endocrinology
|
|
Tulobuterol (hydrochloride) (Standard) is the analytical standard of Tulobuterol (hydrochloride). This product is intended for research and analytical applications. Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength . Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation .
|
-
- HY-14299R
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
|
-
- HY-18862
-
|
|
p38 MAPK
|
Inflammation/Immunology
|
|
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .
|
-
- HY-N2807
-
-
- HY-150579
-
|
|
Keap1-Nrf2
|
Inflammation/Immunology
Cancer
|
|
Keap1-Nrf2-IN-13 is a Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with an IC50 value of 0.15 μM. Keap1-Nrf2-IN-13 has strong binding affinities to the Keap1 protein by forming hydrogen bond with the key polar residues (Asn414, Arg415, Arg483, Gln530). Keap1-Nrf2-IN-13 can be used in the research of oxidative stress-related and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD) and cancers .
|
-
- HY-14299AR
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
|
-
- HY-163702
-
|
|
Adrenergic Receptor
mAChR
|
Inflammation/Immunology
|
|
CHF-6550 is an antagonist for muscarinic M3 receptor and an agonist for β2 adrenoceptor (MABA), with pKi of 9.3 and 10.6, respectively. CHF-6550 exhibits good hepatocyte clearance in rat models and good pharmacokinetic characteristics in guinea pigs .
|
-
- HY-B0809R
-
|
1,3-Dimethylxanthine(Standard); Theo-24 (Standard)
|
Phosphodiesterase (PDE)
Adenosine Receptor
HDAC
Apoptosis
Interleukin Related
TNF Receptor
Endogenous Metabolite
|
Cancer
|
|
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-163982
-
|
|
Others
|
Inflammation/Immunology
|
|
FOXJ1 agonist 1 (compound 16c) is an orally effective small molecule that can effectively enhance the expression of FOXJ1. Foxj1-IN-1 acts on the mammalian airway system composed of multiciliated cells (MCC) to prevent the development and onset of chronic obstructive pulmonary disease (COPD). Foxj1-IN-1 can induce the production of motile cilia in the respiratory system of zebrafish and mammals, and inhibit elastase-induced COPD mouse models. Foxj1-IN-1 has good liver microsomal stability, in vivo PK curve and AUC; it has no significant inhibition of CYP and hERG, and does not have significant cytotoxicity .
|
-
- HY-N0567
-
|
Safflomin A; HSYA
|
Apoptosis
Autophagy
|
Cardiovascular Disease
Cancer
|
|
Hydroxysafflor yellow A (Safflomin A) is a natural product of flavonoids isolated from safflower. Hydroxysafflor yellow A can inhibit cell proliferation and promote apoptosis through the autophagy pathway. Hydroxysafflor yellow A has anti-inflammatory, antioxidant and antitumor effects. Hydroxysafflor yellow A can be used in the study of cardiovascular disease .
|
-
- HY-N0567R
-
|
|
Apoptosis
Autophagy
|
Cardiovascular Disease
Cancer
|
|
Hydroxysafflor yellow A (Standard) is the analytical standard of Hydroxysafflor yellow A. This product is intended for research and analytical applications. Hydroxysafflor yellow A (Safflomin A) is a natural product of flavonoids isolated from safflower. Hydroxysafflor yellow A can inhibit cell proliferation and promote apoptosis through the autophagy pathway. Hydroxysafflor yellow A has anti-inflammatory, antioxidant and antitumor effects. Hydroxysafflor yellow A can be used in the study of cardiovascular disease .
|
-
- HY-106006
-
|
|
PI3K
|
Others
Inflammation/Immunology
|
|
RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ). RV-1729 identifies inhibition of the PI3K isotype by quantifying the release of phosphatidylinositol 3,4, 5-triphosphate (PIP3) (IC50=12 nM), showing twice the selectivity for PI3Kδ relative to PI3Kγ. RV-1729 is also 16 times more selective to PI3Kα. RV-1729 regulates immune and inflammatory responses by inhibiting PI3Kδ. RV-1729 can be used in studies of asthma and chronic obstructive pulmonary disease (COPD) .
|
-
- HY-148525
-
|
β2AR/M-receptor agonist-2
|
mAChR
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
β2AR/M-receptor agonist-2 (compound 15) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-2 shows potency to β2 adrenoceptor with an EC50 value of 3.7 nM. β2AR/M-receptor agonist-2 also has potency to human cloned M3 receptor with a Ki value of 0.73 nM. β2AR/M-receptor agonist-2 is a potent bronchodilator, it can be used for the research of chronic obstructive pulmonary disease (COPD) .
|
-
- HY-19519
-
|
DF 2156A free base
|
CXCR
|
Inflammation/Immunology
Cancer
|
Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma .
|
-
- HY-19519A
-
|
DF 2156A
|
CXCR
|
Infection
Inflammation/Immunology
|
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma .
|
-
- HY-103370
-
|
BA 7602-06
|
Chloride Channel
|
Inflammation/Immunology
|
|
Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase . Talniflumate is an orally active Ca 2+-activated Cl - channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome .
|
-
- HY-103445
-
|
|
Elastase
|
Cardiovascular Disease
|
|
SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury . SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases .
|
-
-
-
HY-L134
-
|
|
191 compounds
|
|
Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.
Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 191 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3293
-
|
POL6014
|
Elastase
|
Inflammation/Immunology
|
|
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF) .
|
-
- HY-P3293A
-
|
POL6014 TFA
|
Elastase
|
Inflammation/Immunology
|
|
Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
|
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
-
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
-
- HY-P9923
-
|
MEDI-563; BIW-8405
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1037S
-
|
|
|
Salbutamol-d3 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-B1037S2
-
|
|
|
Salbutamol-d9 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-B0241S
-
|
|
|
Ipratropium-d3 (bromide) is the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC50 values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3].
|
-
-
- HY-B1810S
-
|
|
|
Tulobuterol-d9 (hydrochloride) is the deuterium labeled Tulobuterol. Tulobuterol (C-78 free base) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol is also a sympathomimetic agent used as a transdermal patch, and increases normal diaphragm muscle strength[1].
|
-
-
- HY-B0809S1
-
|
|
|
Theophylline-d3 is deuterated labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
|
-
-
- HY-B1037S3
-
|
|
|
Salbutamol-d9 (acetate) is the deuterium labeled Salbutamol[1]. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-B0241S1
-
|
|
|
Ipratropium-d7 (bromide)eis the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC50 values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
